title: CCK2 receptor antagonists: pharmacological tools to study the gastrin-ECL cell-parietal cell axis.
abstract: Gastrin-recognizing CCK2 receptors are expressed in parietal cells and in so-called ECL cells in the acid-producing part of the stomach. ECL cells are endocrine/paracrine cells that produce and store histamine and chromogranin A (CGA)-derived peptides, such as pancreastatin. The ECL cells are the principal cellular transducer of the gastrin-acid signal. Activation of the CCK2 receptor results in mobilization of histamine (and pancreastatin) from the ECL cells with consequent activation of the parietal cell histamine H2 receptor. Thus, release of ECL-cell histamine is a key event in the process of gastrin-stimulated acid secretion. The oxyntic mucosal histidine decarboxylase (HDC) activity and the serum pancreastatin concentration are useful markers for the activity of the gastrin-ECL cell axis. Powerful and selective CCK2 receptor antagonits have been developed from a series of benzodiazepine compounds. These agents are useful tools to study how gastrin controls the ECL cells. Conversely, the close control of ECL cells by gastrin makes the gastrin-ECL cell axis well suited for evaluating the antagonistic potential of CCK2 receptor antagonists with the ECL-cell HDC activity as a notably sensitive and reliable parameter. The CCK2 receptor antagonists YF476, YM022, RP73870, JB93182 and AG041R were found to cause prompt inhibition of ECL-cell histamine and pancreastatin secretion and synthesis. The circulating pancreastatin concentration is raised, was lowered when the action of gastrin on the ECL cells was blocked by the CCK2 receptor antagonists. These effects were associated with inhibition of gastrin-stimulated acid secretion. In addition, sustained receptor blockade was manifested in permanently decreased oxyntic mucosal HDC activity, histamine concentration and HDC mRNA and CGA mRNA concentrations. CCK2 receptor blockade also induced hypergastrinemia, which probably reflects the impaired gastric acid secretion (no acid feedback inhibition of gastrin release). Upon withdrawal of the CCK2 receptor antagonists, their effects on the ECL cells were readily reversible. In conclusion, gastrin mobilizes histamine from the ECL cells, thereby provoking the parietal cells to secrete acid. While CCK2 receptor blockade prevents gastrin from evoking acid secretion, it is without effect on basal and vagally stimulated acid secretion. We conclude that specific and potent CCK2 receptor antagonists represent powerful tools to explore the functional significance of the ECL cells.
authors.affiliation: Department of Pharmacology, University of Lund, Sweden.
authors.forename: R
authors.initials: R
authors.lastname: Håkanson
authors.forename: X Q
authors.initials: XQ
authors.lastname: Ding
authors.forename: P
authors.initials: P
authors.lastname: Norlén
authors.forename: E
authors.initials: E
authors.lastname: Lindström
mesh_terms: D000818:Animals; D001569:Benzodiazepines / Q000494:pharmacology; D001570:Benzodiazepinones / Q000378:metabolism / Q000494:pharmacology; D053379:Chromogranin A; D005744:Gastric Acid / Q000378:metabolism; D005753:Gastric Mucosa / Q000378:metabolism*; D005755:Gastrins / Q000378:metabolism*; D006632:Histamine / Q000378:metabolism; D006640:Histidine Decarboxylase / Q000187:drug effects / Q000378:metabolism; D006727:Hormone Antagonists / Q000494:pharmacology*; D006801:Humans; D007211:Indoles / Q000378:metabolism / Q000494:pharmacology; D010187:Pancreatic Hormones / Q000378:metabolism; D010295:Parietal Cells, Gastric / Q000166:cytology / Q000187:drug effects / Q000378:metabolism*; D010671:Phenylurea Compounds / Q000378:metabolism / Q000494:pharmacology; D043887:Receptor, Cholecystokinin B; D011949:Receptors, Cholecystokinin / Q000037:antagonists & inhibitors* / Q000378:metabolism; D013270:Stomach / Q000166:cytology / Q000187:drug effects
chemical_list: C109755:AG-041R; D001570:Benzodiazepinones; D053379:Chromogranin A; D005755:Gastrins; D006727:Hormone Antagonists; D007211:Indoles; D010187:Pancreatic Hormones; D010671:Phenylurea Compounds; C094193:RP 73870; D043887:Receptor, Cholecystokinin B; D011949:Receptors, Cholecystokinin; C050836:pancreastatin; D001569:Benzodiazepines; C087260:YM 022; D006632:Histamine; D006640:Histidine Decarboxylase; C104428:YF 476